Phase 1/2 study of venetoclax, a BCL-2 inhibitor, in Japanese patients with relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma.

已完结 10 由 jxxjxx 发布于 2025/7/4 16:53:07

DOI:10.1007/s12185-020-03024-3
作者：Koji Izutsu, Kazuhito Yamamoto, Koji Kato, Takayuki Ishikawa, Noriko Fukuhara, Yasuhito Terui, Ilseung Choi, Kathryn Humphrey, Su Young Kim, Sumiko Okubo,&
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1007/s12185-020-03024-3

Springer

Abstract：Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have limited treatment options. Venetoclax is a potent BCL-2 inhibitor that ind

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:SpringerBCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.